Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

Next Previous
Search
Trial Profile

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UCART20x22 (Primary) ; Alemtuzumab; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Acronyms NatHaLi-01
  • Sponsors Cellectis

    • Most Recent Events

    • 04 Nov 2024 According to a Cellectis media release, the company expect to present the Phase 1 dataset and late-stage development strategy in 2025.
    • 28 May 2024 According to a Cellectis media release, company is expected to provide updates in the advancements of BALLI-01 and NATHALI-01 by year-end 2024.
    • 12 Dec 2023 Results (N=3, as of 01 July 2023) assessing preliminary data from the NatHaLi-01 trial the first-in-human Phase 1/2a dose-finding and expansion study evaluating UCART20x22 in R/R B-cell NHL, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top